Concepedia

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer

Miso Kim, Bhumsuk Keam, Tae‐Min Kim, Hoon-Gu Kim, Jin-Soo Kim, Sung Sook Lee, Seong Hoon Shin, Min Kyoung Kim, Keon Uk Park, Dong‐Wan Kim,

Cancer Research and Treatment · 2016 · 29 citations · 18 references

DOIFull text

Open access

Abstract

Irinotecan and cisplatin combination chemotherapy showed modest anti-tumour activity and manageable toxicity for patients with metastatic, unresectable esophageal cancer.

References

18

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Global cancer statistics, 2012

Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.2K citations · Full text

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012

Kyu‐Won Jung, Young‐Joo Won, Hyun-Joo Kong et al. · Cancer Research and Treatment · 2015 · 1.2K citations · Full text

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer

Harry Bleiberg, Thierry Conroy, B Paillot et al. · European Journal of Cancer · 1997 · 347 citations

, , +7

Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esophageal Cancer

David H. Ilson, Leonard B. Saltz, Peter C. Enzinger et al. · Journal of Clinical Oncology · 1999 · 265 citations